Every night, the online Belgian patent register ('eRegister') receives an update with public data that were entered or generated the preceding day on the Benelux Patent Platform, the computer application with which the Belgian Intellectual Property Office handles the registration, treatment and publication processes for patents and supplementary protection certificates.
Currently, some updates are spread over consecutive nights due to the large, weekly volume of data concerning European patents designating Belgium.
For a European patent it is possible that data about the inventor(s) are missing from the online Belgian patent register. They can be found via the link to the European patent register pending an update of the Belgian patent register.
For European patents with Unitary Effect, the authentic source of information is the European Patent Register : please refer to it.

Patent details

4176048 Title: LYMPHOCYTES T GÉNÉTIQUEMENT MODIFIÉS À INTERRUPTION DE REGNASE-1 ET/OU DE TGFBRII AYANT UNE FONCTIONNALITÉ ET UNE PERSISTANCE AMÉLIORÉES

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic information

Application number:
217870427
WO application number:
IB2021058704
Type:
European patent granted for BE
Status:
Lapsed
Publication number:
4176048
WO publication number:
WO2022064428
1rst applicant's nationality:
Translation language:
EPO publication language:
English
SPC number:

Dates

Filing date:
23/09/2021
Grant date:
11/09/2024
EP publication date:
10/05/2023
WO publication date:
31/03/2022
Claims translation received date:
Translation received date (EP publication B1):
Translation received date (EP publication B2):
Translation received date (EP publication B3):
Registration date:
11/09/2024
EP B1 publication date:
11/09/2024
EP B2 publication date:
EP B3 publication date:
Lapsed date:
30/09/2024
Expiration date (if granted and all annual fees paid):
23/09/2041

Applicant

Name:
CRISPR Therapeutics AG
Legal Form:
From:
11/09/2024
Address:
Baarerstrasse 14, 6300 Zug, Switzerland (CH)
To:

Inventor

1

Name:
DEQUEANT, Mary-Lee
Legal Form:
Address:
Cambridge, Massachusetts 02139, United States (US)

2

Name:
KALAITZIDIS, Demetrios
Legal Form:
Address:
Cambridge, Massachusetts 02139, United States (US)

3

Name:
GHONIME, Mohammed
Legal Form:
Address:
Cambridge, Massachusetts 02139, United States (US)

Priority

1

Priority patent number:
202163225673 P
Priority date:
26/07/2021
Priority country:
United States (US)

2

Priority patent number:
202063124429 P
Priority date:
11/12/2020
Priority country:
United States (US)

3

Priority patent number:
202063082357 P
Priority date:
23/09/2020
Priority country:
United States (US)

Classification

IPC or IDT classification:
A61K 39/00; C12N 5/0783; A61K 35/17; A61K 38/00; C12N 15/113; C12N 15/90; A61K 48/00;

Publication

Bulletin

1

Bulletin heading:
EP2
Journal edition number:
2024/17
Publication date:
04/11/2024
Description:
Contains data concerning European patents granted and published (B1 publication) for Belgium and for which no translation needed to be filed

2

Bulletin heading:
VRV
Journal edition number:
2025/09
Publication date:
10/07/2025
Description:
Contains data concerning lapse, annulment or rejection of patent(s) (applications) and SPC (applications)

European Patent Bulletin

Issue number:
202437
Publication date:
11/09/2024
Description:
Grant (B1)

Annual fee

Annual fee(s) Due Date:
Annual fee number:
Expected payer:
Last annual fee payment date:
Last annual fee paid number:
Payer:
Filing date Document type Publication Type Document Description Number of pages File Type